Chemours (NYSE:CC) Stock Moved Down to Hold by Mizuho

Chemours (NYSE:CC) was downgraded by stock analysts at Mizuho from a “strong-buy” rating to a “hold” rating in a research report issued on Tuesday, Zacks reports.

CC has been the topic of a number of other research reports. Barclays assumed coverage on Chemours in a research note on Monday. They issued an “equal weight” rating and a $16.00 target price on the stock. Weiss Ratings lowered Chemours from a “sell (d)” rating to a “sell (d-)” rating in a research note on Thursday, August 6th. Morgan Stanley set a $18.00 price target on Chemours in a research note on Monday, August 10th. UBS Group cut their price objective on Chemours from $18.00 to $16.00 and set a “neutral” rating for the company in a report on Monday, October 5th. Finally, Royal Bank Of Canada cut Chemours from an “outperform” rating to a “sector perform” rating and set a $14.00 price objective for the company. in a report on Tuesday. Three research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $18.09.

Chemours Price Performance

Shares of NYSE:CC opened at $12.81 on Tuesday. The company’s fifty day moving average price is $14.79 and its 200-day moving average price is $18.97. The company has a debt-to-equity ratio of 18.98, a current ratio of 1.66 and a quick ratio of 0.88. The firm has a market capitalization of $1.93 billion, a price-to-earnings ratio of -6.71 and a beta of 1.41. Chemours has a one year low of $10.44 and a one year high of $28.67.

Chemours (NYSE:CC) last posted its quarterly earnings data on Tuesday, August 4th. The specialty chemicals company reported $0.42 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.49 by ($0.07). Chemours had a positive return on equity of 60.64% and a negative net margin of 5.00%. The company had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $1.65 billion. During the same period in the prior year, the firm posted ($2.54) earnings per share. The business’s revenue was down 1.5% on a year-over-year basis. On average, equities research analysts anticipate that Chemours will post 0.84 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Chemours news, CEO Denise Dignam acquired 3,378 shares of the stock in a transaction dated Tuesday, August 11th. The stock was purchased at an average cost of $14.95 per share, for a total transaction of $50,501.10. Following the acquisition, the chief executive officer owned 339,916 shares in the company, valued at $5,081,744.20. The trade was a 1.00% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Calderon Gerardo Familiar acquired 1,935 shares of the stock in a transaction dated Wednesday, August 12th. The stock was acquired at an average price of $15.53 per share, with a total value of $30,050.55. Following the completion of the acquisition, the insider owned 58,547 shares in the company, valued at approximately $909,234.91. The trade was a 3.42% increase in their position. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders have acquired 8,663 shares of company stock valued at $130,601. 0.85% of the stock is currently owned by corporate insiders.

Institutional Trading of Chemours

Several hedge funds have recently added to or reduced their stakes in CC. Wedmont Private Capital purchased a new stake in Chemours during the third quarter valued at about $145,000. Engineers Gate Manager LP grew its stake in shares of Chemours by 24.6% during the second quarter. Engineers Gate Manager LP now owns 91,650 shares of the specialty chemicals company’s stock valued at $1,881,000 after buying an additional 18,106 shares during the last quarter. Integrated Wealth Concepts LLC purchased a new position in shares of Chemours in the second quarter worth about $125,000. Nykredit A S purchased a new position in shares of Chemours in the second quarter worth about $99,000. Finally, Corient Private Wealth LP increased its holdings in shares of Chemours by 12.6% in the second quarter. Corient Private Wealth LP now owns 30,644 shares of the specialty chemicals company’s stock worth $629,000 after buying an additional 3,432 shares during the period. 76.26% of the stock is owned by institutional investors.

Key Headlines Impacting Chemours

Here are the key news stories impacting Chemours this week:

• Positive Sentiment: BMO Capital reaffirmed its Buy rating, indicating that some analysts still see recovery potential in Chemours despite the recent weakness. BMO Capital reaffirms Buy rating
• Neutral Sentiment: Barclays initiated coverage at Equal Weight, while Mizuho maintained a Neutral rating but reduced its price target to $15 from $18. The new target still implies potential upside from recent trading levels, but the cut signals more cautious expectations. Mizuho downgrades Chemours
• Negative Sentiment: RBC Capital downgraded Chemours to Sector Perform from Outperform and cut its price target to $14 from $22, citing persistent TiO₂ weakness, soft chemical demand and potential headwinds in the Thermal & Specialized Solutions segment through year-end. RBC downgrades Chemours
• Negative Sentiment: Several law firms announced or promoted a securities-fraud class action filed against Chemours and certain officers. The case covers investors who purchased shares from February 20 through August 4, 2026, and alleges investors were harmed by disclosures concerning Opteon refrigerant aftermarket demand. The lead-plaintiff deadline is December 7, 2026. Although the allegations have not been proven, the litigation creates legal, financial and reputational risks. Chemours securities-fraud class action

About Chemours

The Chemours Company (NYSE: CC) is a global chemical company that develops, manufactures and distributes specialty chemical products used in a range of industrial and consumer applications. Its portfolio serves markets including coatings, plastics, automotive, refrigeration and air conditioning, electronics, telecommunications, energy, healthcare and general manufacturing.

Chemours operates through three primary business segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials.